RSLS - ReShape Lifesciences Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
11,489
607
1,287
787
Cost of Revenue
3,927
164
936
431
Gross Profit
7,561
442
351
355
Operating Expenses
Research Development
3,051
5,722
5,775
5,169
Selling General and Administrative
21,886
19,262
25,984
17,982
Total Operating Expenses
24,937
24,984
31,759
23,151
Operating Income or Loss
-17,375
-24,541
-31,408
-22,796
Interest Expense
-
12
4
4,104
Total Other Income/Expenses Net
-36,106
-14,160
-4,722
3,533
Income Before Tax
-53,883
-38,714
-36,133
-23,361
Income Tax Expense
-911
-3,447
-2,315
-
Income from Continuing Operations
-52,972
-35,267
-33,818
-23,361
Net Income
-76,813
-81,152
-33,818
-23,361
Net Income available to common shareholders
-75,918
-84,231
-33,818
-23,361
EBITDA
-
-24,101
-36,129
-19,257